Minghui Pharmaceutical Reports Initial Data from P-I Study of MHB039A for R/R Solid Tumors
Shots:
- The P-I study is assessing safety, PK/PD, preliminary antitumor activity and recommended Phase 2 dose (RP2D) of MHB039A (PD-1 x VEGF bispecific antibody) for the treatment of patients with r/r solid tumors
- Study depicted strong PD-1 receptor occupancy & VEGF biomarker responses at all doses, with 20mg/kg (Q3W) dose showing sustained inhibition of PD-1 & VEGF. Tumor volume also reduced in sqNSCLC, non-sq NSCLC without actionable genomic alterations and EGFR mutated NSCLC in patients after 3rd gen. TKI therapy
- MHB039A was well tolerable up to 20mg/kg, without DLTs and MTD not achieved. The overall safety aligned with prior findings for PD-1 x VEGF bispecific antibodies
Ref: PR Newswire | Image: Minghui Pharmaceutical
Related News:- Zymeworks Reports the First Patient Dosing with ZW191 in P-I Study for Treating Folate Receptor-⍺ Expressing Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
